|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease显示文摘AIM To performed a systematic review and meta-analysis to determine any possible differences in terms of effectiveness, safety and tolerability between existing colon-cleansing products in patients with inflammatory bowel disease.METHODS Systematic searches were performed( January 1980-September 2016) using MEDLINE, EMBASE, Scopus, CENTRAL and ISI Web of knowledge for randomized trials assessing preparations with or without adjuvants, given in split and non-split dosing, and in high(> 3 L) or low-volume(2 L or less) regimens. Bowel cleansing quality was the primary outcome. Secondary outcomes included patient willingness-torepeat the procedure and side effects/complications.RESULTS Out of 439 citations, 4 trials fulfilled our inclusion criteria(n = 449 patients). One trial assessed the impact of adding simethicone to polyethylene glycol(PEG) 4 L with no effect on bowel cleansing quality, but a better tolerance. Another trial compared senna to castor oil, again without any differences in term of bowel cleansing. Two trials compared the efficacy of PEG high-volume vs PEG low-volume associated to an adjuvant in split-dose regimens: PEG low-dose efficacy was not different to PEG high-dose; OR = 0.84(0.37-1.92). A higher proportion of patients were willing to repeat low-volume preparations vs high-volume; OR = 5.11(1.31-20.0). CONCLUSION In inflammatory bowel disease population, PEG lowvolume regimen seems not inferior to PEG high-volume to clean the colon, and yields improved willingness-torepeat. Further additional research is urgently required to compare contemporary products in this population. | Sophie Restellini Omar Kherad Talat Bessissow Charles Ménard Myriam Martel Maryam Taheri Tanjani Peter L Lakatos Alan N Barkun | 2017 | World Journal of Gastroenterology2017，23，32： | 16 |
| 2 | Management of inflammatory bowel disease with Clostridium difficile infection显示文摘AIM To address the management of Clostridium difficile(C. difficile) infection(CDI) in the setting of suspected inflammatory bowel disease(IBD)-flare.METHODS A systematic search of the Ovid MEDLINE and EMBASE databases by independent reviewers identified 70 articles including a total of 932141 IBD patients or IBDrelated hospitalizations. RESULTS In those with IBD,CDI is associated with increased morbidity,including subsequent escalation in IBD medical therapy,urgent colectomy and increased hospitalization,as well as excess mortality. Vancomycincontaining regimens are effective first-line therapies for CDI in IBD inpatients. No prospective data exists with regards to the safety or efficacy of initiating or maintaining corticosteroid,immunomodulator,or biologic therapy to treat IBD in the setting of CDI. Corticosteroid use is a risk factor for the development of CDI,while immunomodulators and biologics are not. CONCLUSION Strong recommendations regarding when to initiate IBD specific therapy in those with CDI are precluded by a lack of evidence. However,based on expert opinion and observational data,initiation or resumption of immunosuppressive therapy after 48-72 h of targeted antibiotic treatment for CDI may be considered. | Julie D’Aoust Robert Battat Talat Bessissow | 2017 | World Journal of Gastroenterology2017，23，27： | 14 |
| 3 | Endoscopic management of Crohn's strictures显示文摘Symptomatic intestinal strictures develop in more than one third of patients with Crohn's disease(CD) within 10 years of disease onset. Strictures can be inflammatory, fibrotic or mixed and result in a significant decline in quality of life, frequently requiring surgery for palliation of symptoms. Patients under the age of 40 with perianal disease are more likely to suffer from disabling ileocolonic disease thus may have a greater risk for fibrostenotic strictures. Treatment options for fibrostenotic strictures are limited to endoscopic and surgical therapy. Endoscopic balloon dilatation(EBD) appears to be a safe, less invasive and effective alternative modality to replace or defer surgery. Serious complications are rare and occur in less than 3% of procedures. For non-complex strictures without adjacent fistulizaation or perforation that are less than 5 cm in length, EBD should be considered as first-line therapy. The aim of this review is to present the current literature on the endoscopic management of small bowel and colonic strictures in CD, which includes balloon dilatation, adjuvant techniques of intralesional injection of steroids and anti-tumor necrosis factor, and metal stent insertion. Short and long-term outcomes, complications and safety of EBD will be discussed. | Talat Bessissow Jason Reinglas Achuthan Aruljothy Peter L Lakatos Gert Van Assche | 2018 | World Journal of Gastroenterology2018，24，17： | 10 |
| 4 | Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: a review article显示文摘Emerging data have highlighted the co-existence of nonalcoholic fatty liver disease(NAFLD) and inflammatory bowel disease; both of which are increasingly prevalent disorders with significant complications and impact on future health burden. Cross-section observational studies have shown widely variable prevalence rates of co-existing disease,largely due to differences in disease definition and diagnostic tools utilised in the studies. Age,obesity,insulin resistance and other metabolic conditions are common risks factors in observational studies. However,other studies have also suggested a more dominant role of inflammatory bowel disease related factors such as disease activity,duration,steroid use and prior surgical intervention,in the development of NAFLD. This suggests a potentially more complex pathogenesis and relationship between the two diseases which may be contributed by factors including altered intestinal permeability,gut dysbiosis and chronic inflammatory response. Commonly used immunomodulation agents pose potential hepatic toxicity,however no definitive evidence exist linking them to the development of hepatic steatosis,nor are there any data on the impact of therapy and prognosis in patient with co-existent diseases. Further studies are required to assess the impact and establish appropriate screening and management strategies in order to allow early identification,intervention and improve patient outcomes. | Che-yung Chao Robert Battat Alex Al Khoury Sophie Restellini Giada Sebastiani Talat Bessissow | 2016 | World Journal of Gastroenterology2016，22，34： | 7 |
| 5 | Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?显示文摘In recent years,there has been a critical change in treatment paradigms in inflammatory bowel diseases(IBD)triggered by the arrival of new effective treatments aiming to prevent disease progression,bowel damage and disability.The insufficiency of symptomatic disease control and the well-known discordance between symptoms and objective measures of disease activity lead to the need of reviewing conventional treatment algorithms and developing new concepts of optimal therapeutic strategy.The treat-to-target strategies,defined by the selecting therapeutic targets in inflammatory bowel disease consensus recommendation,move away from only symptomatic disease control and support targeting composite therapeutic endpoints(clinical and endoscopical remission)and timely assessment.Emerging data suggest that early therapy using a treat-to-target approach and an algorithmic therapy escalation using regular disease monitoring by clinical and biochemical markers(fecal calprotectin and C-reactive protein)leads to improved outcomes.This review aims to present the emerging strategies and supporting evidence in the current therapeutic paradigm of IBD including the concepts of“early intervention”,“treat-to-target”and“tight control”strategies.We also discuss the real-word experience and applicability of these new strategies and give an overview on the future perspectives and areas in need of further research and potential improvement regarding treatment targets and(“tight”)disease monitoring strategies. | Lorant Gonczi Talat Bessissow Peter Laszlo Lakatos | 2019 | World Journal of Gastroenterology2019，25，41： | 4 |
| 6 | Surgery in Castleman?s Disease: A Systematic Review of 404 Published Cases显示文摘 | Nadia Talat Ajay P. Belgaumkar Klaus-Martin Schulte | 2012 | Annals of Surgery2012，，4： | 3 |
| 7 | Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases显示文摘The past decade has brought substantial advances in the management of inflammatory bowel diseases(IBD). The introduction of tumor necrosis factor(TNF) antagonists, evidence for the value of combination therapy, the recog-nition of targeting lymphocyte trafficking and activation as a viable treatment, and the need for early treatment of high-risk patients are all fundamental concepts for current modern IBD treatment algorithms. In this article, authors review the existing data on approved biologicals and small molecules as well as provide insight on the current positioning of approved therapies. Patient stratification for the selection of specific therapies, therapeutic targets and patient monitoring will be discussed as well. The thera-peutic armamentarium for IBD is expanding as novel and more targeted therapies become available. In the absence of comparative trials, positioning these agents is becoming difficult. Emerging concepts for the future will include an emphasis on the development of algorithms which will facilitate a greater understanding of the positioning of novel biological drugs and small molecules in order to best tailor therapy to the patient. In the interim, anti-TNF therapy remains an important component of IBD therapy with the most real-life evidence and should be considered as first-line therapy in patients with complicated Crohn's disease and in acute-severe ulcerative colitis. The safety and efficacy of these ‘older' anti-TNF therapies can be optimized by adhering to therapeutic algorithms which combine clinical and objective markers of disease severityand response to therapy. | Jason Reinglas Lorant Gonczi Zsuzsanna Kurt Talat Bessissow Peter L Lakatos | 2018 | World Journal of Gastroenterology2018，24，32： | 3 |
| 8 | Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?显示文摘Inflammatory bowel disease(IBD) is a lifelong, progres-sive disease that has disabling impacts on patient's lives. Given the complex nature of the diagnosis of IBD and its management there is consequently a large economic burden seen across all health care systems. Quality in-dicators(QI) have been created to assess the different fa?ades of disease management including structure, process and outcome components. Their development serves to provide a means to target and measure quality of care(Qo C). Multiple different QI sets have been published in IBD, but all serve the same purpose of trying to achieve a standard of care that can be attained on a national and international level, since there is still a major variation in clinical practice. There have been many recent innovative developments that aim to improve Qo C in IBD including telemedicine, home biomarker assessment and rapid access clinics. These are some of the novel advancements that have been shown to have great potential at improving Qo C, while offloading some of the burden that IBD can have vis-a-vis emergency room visits and hospital admissions. The aim of the current review is to summarize and discuss available QI sets and recent developments in IBD care including telemedicine, and to give insight into how the utilization of these tools could benefit the Qo C of IBD patients. Additionally, a treating-to-target structure as well as evidence surrounding aggressive management directed at tighter disease control will be presented. | Matthew Strohl Lorant Gonczi Zsuzsanna Kurt Talat Bessissow Peter L Lakatos | 2018 | World Journal of Gastroenterology2018，24，22： | 2 |
| 9 | Removal of Cr(VI) from aqueous solutions using wheat bran 显示文摘 | Singh K K Hasan S H Talat M | 2009 | ChemEngJ2009，151，123： | 1 |
| 10 | A review of secondary sludge reduction technologies for the paper industry 显示文摘 | Talat Mahmood Allan Elliott | 2006 | Water Re- search2006，40，11： | 1 |
| 11 | Biosynthesis of gold and silver nanoparticles by natural precursor clove and their functionalization with amine group显示文摘 | Singh A K Talat M Singh D P | 2010 | Nanopart Res2010，12，5： | 1 |
| 12 | Th1/Th2 cytomet- rie bead array can discriminate cytokine secretion from endogenously activated cells in pulmonary disease, re- cent and remote infection in tuberculosis显示文摘 | Talat N Shahid F Perry S | 2011 | Cytokine2011，54，2： | 1 |
| 13 | Surgery in Castleman′s disease:a systematic review of 404 published cases显示文摘 | Talat N Belgaumkar AP Schulte KM | 2012 | Ann Surg2012，255，4： | 1 |
| 14 | A review of secondary sludge reduction technologies for the pulp and paper industry显示文摘 | Talat Mahmood A E | 2006 | Water Research2006，40，： | 1 |
| 15 | Stat3 activation is required for the growth of U87 cell-derived tumours in mice显示文摘 | Atreyi Dasgupta Baisakhi Raychaudhuri Talat Haqqi Richard Prayson Erwin G. Van Meir Michael Vogelbaum Saikh Jaharul Haque | 2008 | European Journal of Cancer2008，，4： | 1 |
| 16 | Anomalous Ionospheric foF2 Variations Observed Prior to the Dalbandin Earthquake in Pakistan显示文摘Ionosphereic foF2 variations are very sensitive to the seismic effect and results of ionospheric perturbations associated with earthquakes seem to very hopeful for short-term earthquake prediction. On January 18,2011 at 20: 23 UT a great earthquake( M = 7. 2)occurred in Dalbandin( 28. 73° N,63. 92° E),Pakistan. In this study,we have tried to find out the features of pre-earthquake ionospheric anomalies by using the hourly day time( 08. 00 a. m.- 05. 00 p. m.) data of critical frequency( foF2) obtained by three vertical sounding stations installed in Islamabad( 33. 78°N,73. 06°E),Multan( 32. 26°N,71. 51°E) and Karachi( 24. 89° N,67. 02° E), Pakistan. The results show the significant anomalies of foF2 in the earthquake preparation zone several days prior to the Dalbandin earthquake. It is also observed that the amplitude and frequency of foF2 anomalies are more prominent at the nearest station to the epicenter as compared to those stations near the outer margin of the earthquake preparation zone. The confidence level for ionospheric anomalies regarding the seismic signatures can be enhanced by adding the analysis of some other ionospheic parameters along with critical frequency of the layer F2. | Muhammad Irfan Aftab Alam Muhammad Junaid Muhammad Ayyaz Ameen Talat Iqbal Huang Fuqiong | 2015 | Earthquake Research in China2015，29，4： | 1 |
| 17 | Tribological behaviors of carbon filled polytetrafluoroethylene (PTFE) dry journal bearings 显示文摘 | Talat Tevruz | 1998 | Wear1998，221，： | 1 |
| 18 | Biosorption of Pb(Ⅱ) from water using biomass of Aeromonas hydrophila: central composite design for optimization of process variables显示文摘 | Hasana S H Srivastavaa P Talat M | 2009 | J Hazard Mater2009，168，： | 1 |
| 19 | Castleman's disease-a two compartment model of HHV8 infection显示文摘 | Schulte KM Talat N | 2010 | Nature Rev Clin Oncol2010，7，： | 1 |
| 20 | Application of response surface methodology for the determination of optimum reaction conditions(temperature and pH) for starch hydrolysis by α-amylase显示文摘 | JAISWAL N PRAKASH O TALAT M | 2011 | Asian J Biochem2011，6，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员